Impact of NMT1 Gene Polymorphisms on Features of the Metabolic Syndrome among Severely Obese Patients

Authors

  • Stéphanie Bégin Institute of Nutrition and Functional Foods (INAF), Laval University, Quebec, QC, Canada; School of Nutrition, Laval University, Quebec, QC, Canada
  • Frédéric Guénard Institute of Nutrition and Functional Foods (INAF), Laval University, Quebec, QC, Canada; School of Nutrition, Laval University, Quebec, QC, Canada
  • André Tchernof School of Nutrition, Laval University, Quebec, QC, Canada; Quebec Heart and Lung Institute, Quebec, QC, Canada
  • Yves Deshaies Quebec Heart and Lung Institute, Quebec, QC, Canada; Department of Medicine, Laval University, Quebec, QC, Canada
  • Louis Pérusse Institute of Nutrition and Functional Foods (INAF), Laval University, Quebec, QC, Canada; Department of Kinesiology, Laval University, Quebec, QC, Canada
  • Simon Biron Quebec Heart and Lung Institute, Quebec, QC, Canada; Department of Surgery, Laval University, Quebec, QC, Canada
  • Odette Lescelleur Quebec Heart and Lung Institute, Quebec, QC, Canada; Department of Surgery, Laval University, Quebec, QC, Canada
  • Laurent Biertho Quebec Heart and Lung Institute, Quebec, QC, Canada; Department of Surgery, Laval University, Quebec, QC, Canada
  • Simon Marceau Quebec Heart and Lung Institute, Quebec, QC, Canada; Department of Surgery, Laval University, Quebec, QC, Canada

DOI:

https://doi.org/10.17140/OROJ-2-116

Keywords:

Obesity; Epigenetics; Genomics; Lipids; Insulin; Myristoylation

Abstract

Introduction: N-myristoyltransferase (NMT) is implicated in myristoylation, required for biological activities of several proteins. Its gene N-myristoyltransferase 1 (NMT1) has been found
to be overexpressed and hypermethylated in Visceral Adipose Tissue (VAT) of severely obese
individuals with Metabolic Syndrome (MetS+) versus without (MetS-).
Objective: The aim of this study was to verify the associations between NMT1 gene polymorphisms Single Nucleotide Polymorphisms (SNPs) and metabolic complications among obese
subjects.
Methods: Associations between SNPs and determinants of MetS were tested with 1752 obese
participants undergoing a bariatric surgery. The effect of selected SNPs on methylation, and
correlation with expression levels of NMT1 were verified in subgroups.
Results: Rs2239921 was significantly associated with systolic (p=0.03) and diastolic (p<0.0001)
blood pressures. Rs2239923 was associated with plasma High Density Lipoprotein-Cholesterol
or HDL-Cholesterol (HDL-C) levels (p=0.05), while rs2269746 was associated with Low Density Lipoprotein-Cholesterol or LDL-Cholesterol (LDL-C) (p=0.006) and Total-Cholesterol
(Total-C) levels (p=0.004). Rs1005136 (p=0.03), rs8066395 (p=0.03) or rs2157840 (p=0.04)
were associated with plasma concentrations of C-Reactive Protein (CRP). Phenotype-associated SNPs were associated with NMT1 methylation levels of six CpG sites. NMT1 methylation
levels of one CpG site, cg10755730, correlated with gene expression levels (r=0.57; p=0.04).
Conclusion: These results suggest that the presence of NMT1 SNPs is associated with altered
plasma lipid levels as well as with increased inflammation markers and blood pressure among
severely obese patients.

References

Albuquerque D, Stice E, Rodriguez-Lopez R, et al. Current re-view of genetics of human obesity: from molecular mechanisms to an evolutionary perspective. Molecular genetics and genom-ics: MGG. 2015; 290(4): 1191-1221. doi: 10.1007/s00438-015- 1015-9

Bluher M. Adipose tissue dysfunction contributes to obesity related metabolic diseases. Best practice & research Clinical en-docrinology & metabolism. 2013; 27: 163-177. doi: 10.1016/j. beem.2013.02.005

Hamer M, Stamatakis E. Metabolically healthy obesity and risk of all-cause and cardiovascular disease mortality. The Jour-nal of clinical endocrinology and metabolism. 2012; 97: 2482- 2488. doi: 10.1210/jc.2011-3475

Milagro FI, Mansego ML, De Miguel C, et al. Dietary factors, epigenetic modifications and obesity outcomes: progresses and perspectives. Molecular aspects of medicine. 2013; 34: 782-812. doi: 10.1016/j.mam.2012.06.010

Bird A. Perceptions of epigenetics. Nature. 2007; 447: 396- 398. doi: 10.1038/nature05913

Larsen F, Gundersen G, Lopez R, et al. CpG islands as gene markers in the human genome. Genomics. 1992; 13: 1095-1107. doi: 10.1016/0888-7543(92)90024-M

Turcot V, Tchernof A, Deshaies Y, et al. LINE-1 methylation in visceral adipose tissue of severely obese individuals is asso-ciated with metabolic syndrome status and related phenotypes. Clinical epigenetics. 2012; 4: 10. doi: 10.1186/1868-7083-4-10

Turcot V, Bouchard L, Faucher G, et al. DPP4 gene DNA methylation in the omentum is associated with its gene expres-sion and plasma lipid profile in severe obesity. Obesity. 2011; 19: 388-395. doi: 10.1038/oby.2010.198

Towler DA, Adams SP, Eubanks SR, et al. Purification and characterization of yeast myristoyl CoA:protein N-myristoyl-transferase. Proceedings of the National Academy of Sciences of the United States of America. 1987; 84: 2708-2712.

Johnson DR, Bhatnagar RS, Knoll LJ, et al. Genetic and biochemical studies of protein N-myristoylation. Annual re-view of biochemistry. 1994; 63: 869-914. doi: 10.1146/annurev. bi.63.070194.004253

Kamata N, Jotte RM, Holt JT. Myristylation alters DNA-binding activity and transactivation of FBR (gag-fos) pro-tein. Molecular and cellular biology. 1991; 11: 765-772. doi: 10.1128/MCB.11.2.765

Hannoush RN. Synthetic protein lipidation. Current opin-ion in chemical biology. 2015; 28: 39-46. doi: 10.1016/j. cbpa.2015.05.025

Thinon E, Serwa RA, Broncel M, et al. Global profiling of co- and post-translationally N-myristoylated proteomes in hu-man cells. Nature communications. 2014; 5: 4919. doi: 10.1038/ ncomms5919

Bouchard L, Tchernof A, Deshaies Y, et al. ZFP36: a promis-ing candidate gene for obesity-related metabolic complications identified by converging genomics. Obesity surgery. 2007; 17: 372-382. doi: 10.1007/s11695-007-9067-5

Guenard F, Tchernof A, Deshaies Y, et al. Differential meth-ylation in visceral adipose tissue of obese men discordant for metabolic disturbances. Physiol Genomics. 2014; 46: 216-222. doi: 10.1152/physiolgenomics.00160.2013

Barros SP, Offenbacher S. Epigenetics: connecting environ-ment and genotype to phenotype and disease. Journal of dental research. 2009; 88: 400-408. doi: 10.1177/0022034509335868

Vohl MC, Sladek R, Robitaille J, et al. A survey of genes dif-ferentially expressed in subcutaneous and visceral adipose tissue in men. Obes Res. 2004; 12: 1217-1222.

Haffner SM. The metabolic syndrome: inflammation, diabetes mellitus, and cardiovascular disease. The American journal of cardiology. 2006; 97: 3A-11A. doi: 10.1016/j.amj-card.2005.11.010

Expert Panel on Detection EaToHBCA. Executive Summary of the Third Report of the National Cholesterol Education Pro-gram (NCEP) Expert Panel on Detection, Evaluation and Treat-ment of High Blood Cholesterol Adults (Adult Treatment Panel III). The Journal of the American Medical Association (JAMA). 2001; 285(19): 2486-2497. doi: 10.1001/jama.285.19.2486

Bakker MI, May L, Hatta M, et al. Genetic, household and spatial clustering of leprosy on an island in Indonesia: a population-based study. BMC Med Genet. 2005; 6: 40. doi: 10.1186/1471-2350-6-40

King MJ, Pugazhenthi S, Khandelwal RL, et al. Mem-brane-associated N-myristoyltransferase activity is reduced in obese (fa/fa) Zucker rat liver. Biochemical and biophysical research communications. 1993; 196: 665-670. doi: 10.1006/ bbrc.1993.2301

Felsted RL, Glover CJ, Hartman K. Protein N-myristoylation as a chemotherapeutic target for cancer. J Natl Cancer Inst. 1995; 87: 1571-1573. doi: 10.1093/jnci/87.21.1571

Dehm SM, Bonham K. SRC gene expression in human can-cer: the role of transcriptional activation. Biochem Cell Biol. 2004; 82: 263-274. doi: 10.1139/o03-077

Buss JE, Kamps MP, Gould K, et al. The absence of myristic acid decreases membrane binding of p60src but does not affect tyrosine protein kinase activity. Journal of virology. 1986; 58: 468-474.

Martin DD, Beauchamp E, Berthiaume LG. Post-translation-al myristoylation: Fat matters in cellular life and death. Biochi-mie. 2011; 93: 18-31. doi: 10.1016/j.biochi.2010.10.018

Burdock GA, Carabin IG. Safety assessment of myristic acid as a food ingredient. Food Chem Toxicol. 2007; 45: 517-529. doi: 10.1016/j.fct.2006.10.009

Ferri N, Paoletti R, Corsini A. Lipid-modified proteins as biomarkers for cardiovascular disease: a review. Biomarkers. 2005; 10: 219-237. doi: 10.1080/13547500500216660

Cui X, Chen J, Fang D. Bioinformatic analyses and an ex-pression study of a novel gene associated with metabolic syn-drome. Biosci Trends. 2010; 4: 165-169.

Cordeddu V, Di Schiavi E, Pennacchio LA, et al. Mutation of SHOC2 promotes aberrant protein N-myristoylation and causes Noonan-like syndrome with loose anagen hair. Nature genetics. 2009; 41: 1022-1026. doi: 10.1038/ng.425

Zhao H, Sun J, Deschamps AM, et al. Myristoylated me-thionine sulfoxide reductase A protects the heart from ischemia-reperfusion injury. Am J Physiol Heart Circ Physiol. 2011; 301: H1513-H1518. doi: 10.1152/ajpheart.00441.2011

Klop B, Elte JW, Cabezas MC. Dyslipidemia in obesity: mechanisms and potential targets. Nutrients. 2013; 5: 1218- 1240. doi: 10.3390/nu5041218

Bell JT, Pai AA, Pickrell JK, et al. DNA methylation patterns associate with genetic and gene expression variation in HapMap cell lines. Genome biology. 2011; 12: R10. doi: 10.1186/gb-2011-12-1-r10

Hedo JA, Collier E, Watkinson A. Myristyl and palmityl ac-ylation of the insulin receptor. The Journal of biological chemis-try. 1987; 262: 954-957.

Sharma RK. Potential role of N-myristoyltransferase in pathogenic conditions. Can J Physiol Pharmacol. 2004; 82: 849-859. doi: 10.1139/y04-099

Shrivastav A, Sharma AR, Bajaj G, et al. Elevated N-my-ristoyltransferase activity and expression in oral squamous cell carcinoma. Oncology reports. 2007; 18: 93-97. doi: 10.3892/ or.18.1.93

Alberti KG, Eckel RH, Grundy SM, et al. Harmonizing the metabolic syndrome: a joint interim statement of the Internation-al Diabetes Federation Task Force on Epidemiology and Pre-vention; National Heart, Lung, and Blood Institute; American Heart Association; World Heart Federation; International Ath-erosclerosis Society; and International Association for the Study of Obesity. Circulation. 2009; 120: 1640-1645. doi: 10.1161/ CIRCULATIONAHA.109.192644

Stancakova A, Laakso M. Genetics of metabolic syndrome. Reviews in endocrine & metabolic disorders. 2014; 15: 243-252. doi: 10.1007/s11154-014-9293-9

Gallagher EJ, Leroith D, Karnieli E. Insulin resistance in obesity as the underlying cause for the metabolic syndrome. Mt Sinai J Med. 2010; 77: 511-523. doi: 10.1002/msj.20212

Hotamisligil GS. Inflammation and metabolic disorders. Na-ture. 2006; 444: 860-867. doi: 10.1038/nature05485

Downloads

Published

2015-11-24

How to Cite

Stéphanie Bégin, Frédéric Guénard, André Tchernof, Yves Deshaies, Louis Pérusse, Simon Biron, … Simon Marceau. (2015). Impact of NMT1 Gene Polymorphisms on Features of the Metabolic Syndrome among Severely Obese Patients. Obesity Research, 101–110. https://doi.org/10.17140/OROJ-2-116

Issue

Volume 2 Issue 4 2015

Section

Articles

License

Creative Commons License

This work is licensed under a Creative Commons Attribution 4.0 International License.

All content published in Obesity Research (OR) is licensed under the Creative Commons Attribution 4.0 International License (CC BY 4.0). This license allows anyone to copy, distribute, transmit, and adapt the work — including for commercial purposes — provided appropriate credit is given to the original author(s) and source.